CN106669033B - Epileptic sleep apnea preventing system capable of being charged safely and rapidly - Google Patents
Epileptic sleep apnea preventing system capable of being charged safely and rapidly Download PDFInfo
- Publication number
- CN106669033B CN106669033B CN201611194592.0A CN201611194592A CN106669033B CN 106669033 B CN106669033 B CN 106669033B CN 201611194592 A CN201611194592 A CN 201611194592A CN 106669033 B CN106669033 B CN 106669033B
- Authority
- CN
- China
- Prior art keywords
- processor
- upper airway
- stimulator
- charging
- battery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001037 epileptic effect Effects 0.000 title claims abstract description 21
- 201000002859 sleep apnea Diseases 0.000 title abstract description 27
- 210000003205 muscle Anatomy 0.000 claims abstract description 43
- 210000001186 vagus nerve Anatomy 0.000 claims abstract description 21
- 238000004891 communication Methods 0.000 claims description 26
- 230000000638 stimulation Effects 0.000 claims description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 239000001301 oxygen Substances 0.000 claims description 19
- 230000000241 respiratory effect Effects 0.000 claims description 18
- 210000005036 nerve Anatomy 0.000 claims description 13
- 206010003497 Asphyxia Diseases 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 8
- 230000002618 waking effect Effects 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 4
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 229910001416 lithium ion Inorganic materials 0.000 claims description 3
- 230000007958 sleep Effects 0.000 claims description 3
- 230000001515 vagal effect Effects 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims 6
- 238000000034 method Methods 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000001133 acceleration Effects 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 240000007839 Kleinhovia hospita Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 101100208306 Acidianus ambivalens tth1 gene Proteins 0.000 description 1
- 101100208381 Caenorhabditis elegans tth-1 gene Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000007384 vagal nerve stimulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36064—Epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3601—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02B—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
- Y02B70/00—Technologies for an efficient end-user side electric power management and consumption
- Y02B70/30—Systems integrating technologies related to power network operation and communication or information technologies for improving the carbon footprint of the management of residential or tertiary loads, i.e. smart grids as climate change mitigation technology in the buildings sector, including also the last stages of power distribution and the control, monitoring or operating management systems at local level
Landscapes
- Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Electrotherapy Devices (AREA)
Abstract
The invention discloses a rapid-charging epileptic sleep apnea prevention system, which comprises a vagus nerve stimulator and an upper airway muscle stimulator, wherein the vagus nerve stimulator comprises a first charging coil, a first main battery, a first temperature sensor, a first standby battery and a first processor; the first processor controls the first charging coil to charge the first main battery and the first standby battery, and controls the first standby battery to charge the first main battery; the upper airway muscle stimulator comprises a second temperature sensor, a second charging coil, a second main battery, a second standby battery and a second processor; the system charges the main battery through the charging coil and the standby battery, and the rapid charging process is controlled through the charging temperature in a closed loop manner, so that the safe and rapid charging of the epileptic sleep apnea prevention system is ensured.
Description
Technical Field
The invention relates to an implanted medical system, in particular to a epileptic sleep apnea preventing system capable of being safely and quickly charged.
Background
Epilepsy is a chronic disease that causes transient brain dysfunction due to sudden abnormal discharge of brain neurons, and the pathogenesis of epilepsy is very complex. The imbalance between central nervous system excitation and inhibition causes epileptic seizures which are not directly fatal, but may cause complications such as sleep apnea and the like, thereby causing suffocation of patients.
US patent 8812098B2 discloses an implanted stimulator that can monitor seizure probability measured for each sleep stage, perform deep brain electrical stimulation to alleviate epileptic symptoms, but cannot prevent sleep apnea.
US patent 6961618B2 discloses that seizures can be monitored based on heart rate, vagal nerve stimulation can be used to alleviate epileptic symptoms, but also fails to prevent the complications of epilepsy, sleep apnea.
Therefore, the method for preventing the asphyxia complications while relieving the epilepsy and ensuring the safe and rapid charging of the epileptic sleep apnea prevention system is a technical problem at present.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide an implantation stimulation system which can monitor the occurrence of asphyxia while relieving epileptic symptoms and perform corresponding muscle stimulation to prevent asphyxia. The system comprises: the device comprises a vagus nerve stimulator and an upper airway muscle stimulator, wherein the vagus nerve stimulator comprises a first electrode, a first pulse generator, a breathing parameter acquisition device, a first temperature sensor, a first charging coil, a first main battery, a first standby battery, a first processor and a first communication module, wherein the first electrode is wound on a vagus nerve; the first processor controls the first charging coil to charge the first main battery and the first standby battery; the first processor controls the first standby battery to charge the first main battery; the first temperature sensor measures a first charging temperature of the vagus nerve stimulator.
The upper airway muscle stimulator comprises a second pulse generator, a second processor, a wake-up module, a second electrode, a second communication module, a second temperature sensor, a second charging coil, a second main battery and a second standby battery; the second electrode is positioned at the upper airway muscle; the second processor controls the second charging coil to charge the second main battery and the second standby battery; the second processor controls the second backup battery to also charge the second main battery, and the second temperature sensor measures a second charging temperature of the upper airway muscle stimulator.
Stopping charging the first main battery by the first processor when the first charging temperature exceeds a threshold; when the second charging temperature exceeds a threshold, the second processor stops charging the second main battery.
The first and second primary batteries and the first and second secondary batteries are lithium ion rechargeable batteries or other rechargeable batteries that can be quickly charged.
The first processor controls the first pulse generator to send pulses to the first electrode wound around the vagus nerve for stimulation according to preset parameters when a patient sleeps, the respiratory parameter sensor collects respiratory parameters such as blood oxygen saturation, judges whether the blood oxygen saturation is lower than a choking threshold, the first communication module is communicated with the second communication module when the blood oxygen saturation is lower than the choking threshold, activates the awakening module and awakens the upper airway muscle stimulator, and the second processor controls the second pulse generator to send pulses to the second electrode at the upper airway muscle according to the preset parameters; the vagus nerve stimulator stimulates the vagus nerve to relieve epileptic symptoms, and when the asphyxia occurs, the upper airway muscle stimulator is aroused to stimulate the upper airway muscle, dilate the upper airway and prevent the asphyxia from occurring.
Further, the device also comprises an in-vitro early warning controller, and when the upper airway muscle stimulator stimulates that the blood oxygen saturation does not rise to a certain threshold value for a period of time, the device carries out early warning on in-vitro communication.
Further, the method further comprises the following steps: when the upper airway muscle stimulator stimulates that the blood oxygen saturation has not risen to a threshold for a period of time, in communication with the vagal nerve stimulator, the first processor sets the pulser parameters to an amplitude that can wake up the patient but that is not damaging to the patient, thereby waking up the patient.
Further, the method further comprises the following steps: the external early warning controller can control pulse parameters of the two stimulator pulse generators.
Further, the method further comprises the following steps: the vagus nerve stimulator can be replaced by deep brain electric stimulator, and can also relieve epileptic symptoms.
The epileptic sleep apnea preventing system can effectively prevent the asphyxia of a patient in sleep in the epileptic treatment process, and improves the life quality of the patient.
Drawings
Fig. 1 is a diagram of an epileptic sleep apnea prevention system of the present invention.
Reference numerals illustrate:
101. a neural electrical stimulator; 102. an upper airway muscle stimulator; 103. an external early warning controller;
201. a first electrode; 202. a first pulse generator; 203. a respiratory parameter acquisition device; 204. a first processor; 205. a first communication module;
301. a second pulse generator; 302. a second processor; 303. a wake-up module; 304. a second electrode; 305. and a second communication module.
Detailed Description
The invention will be further described with reference to the drawings and examples.
First embodiment:
as shown in fig. 1, an epileptic sleep apnea preventing system of the present invention includes a nerve electric stimulator 101 and an upper airway muscle stimulator 102.
The nerve stimulator 101 is an implantable vagal nerve electrical stimulation system (VNS) or an implantable deep brain electrical stimulation system (DBS) for stimulating a target nerve of the patient P, thereby alleviating epileptic symptoms.
The upper airway muscle stimulator 102 is used to stimulate the upper airway muscles of the patient P to dilate the upper airway, thereby preventing the occurrence of choking.
The neurostimulator 101 includes a first electrode 201, a first pulse generator 202, a respiratory parameter acquisition device 203, a first temperature sensor, a first charging coil, a first main battery, a first backup battery, a first processor 204, and a first communication module 205.
The first electrode 201 is a vagus nerve stimulating electrode wound around the vagus nerve of the patient P or a deep brain stimulating electrode implanted in the deep brain of the patient P, and the first electrode 201 is electrically connected to the first pulse generator 202 through an extension lead wire, and the electric stimulation pulse emitted by the first pulse generator 202 is applied to the target nerve to electrically stimulate the nerve target point, thereby generating therapeutic effects.
The first pulse generator 202 is configured to generate corresponding electrical stimulation pulses according to the control of the first processor 204.
The respiratory parameter acquisition device 203 is used to sense one or more physiological parameters of the patient P, such as cardiovascular or cerebrospinal fluid pressure or flow, heart sounds, patient movements or attitudes, temperature, blood oxygen saturation, carbon dioxide, respiratory rate, heart rate, edema or pH, in order to identify the respiratory status of the patient P, preferably the physiological parameters select blood oxygen saturation and respiratory rate. The breathing parameter collection device 203 is one or more sensors for measuring the above-mentioned physiological parameters, preferably the breathing parameter collection device 203 selects a blood oxygen sensor for measuring blood oxygen saturation and an acceleration sensor or bioimpedance sensor for measuring breathing frequency.
The first processor 204 is configured to generate preset pulse parameters under different treatment schemes, determine a respiratory state of the patient P according to the physiological parameters acquired by the respiratory parameter acquisition device 203, generate a wake-up signal for waking up the upper airway muscle stimulator 102 in due time according to the determined respiratory state, and transmit the wake-up signal to the upper airway muscle stimulator 102 through the first communication module 205.
The first processor 204 controls the first charging coil to charge the first main battery and the first backup battery; the first processor 204 controls the first backup battery to also charge the first main battery; the first temperature sensor measures a first charging temperature of the vagus nerve stimulator 101. When the first charging temperature exceeds a threshold, charging of the first main battery is stopped by the first processor 204.
Regarding the determination of abnormal respiratory state of the patient, preferably, the occurrence of sleep apnea, that is, sleep apnea is monitored, specifically, when the acceleration sensor or the bio-impedance sensor does not sample the respiratory signal within the time threshold Tth and the blood oxygen saturation drops beyond the threshold BOth, the first processor 204 determines that sleep apnea occurs and generates the normal mode wake-up signal. Preferably, tth is 8-10 seconds and BOth is 3% -5%.
Preferably, the severity of sleep apnea is further divided, and when the acceleration sensor or bio-impedance sensor does not sample the respiratory signal within the time threshold Tth1 and the blood oxygen saturation drops beyond the threshold BOth1, the first processor 204 determines that mild sleep apnea is occurring and generates an a-mode wake signal; when the acceleration sensor or the bio-impedance sensor does not sample the respiratory signal within the time threshold Tth2 and the blood oxygen saturation drops beyond the threshold BOth2, the first processor 204 determines that the moderate sleep apnea occurs and generates a B-mode wake signal; when the acceleration sensor or the bio-impedance sensor does not sample the respiratory signal within the time threshold Tth3 and the blood oxygen saturation drops beyond the threshold BOth3, the first processor 204 determines that severe sleep apnea occurs and generates a C-mode wake signal. Preferably, tth1 is 8 seconds and BOth1 is 3%; tth2 is 9 seconds, and BOth2 is 4%; tth3 is 10 seconds and BOth3 is 5%.
The first communication module 205 is configured to wirelessly communicate between the neurostimulator 101 and the upper airway muscle stimulator 102 and other devices, wherein the wireless communication may use any technology known in the art, such as RF or bluetooth, etc.
The upper airway muscle stimulator 102 includes a second pulse generator 301, a second processor 302, a wake-up module 303, a second electrode 304, a second temperature sensor, a second charging coil, a second main battery, a second backup battery, a second communication module 305.
The second pulse generator 301 is configured to generate corresponding electrical stimulation pulses according to the control of the second processor 302.
The second processor 302 is configured to generate preset pulse parameters, and preferably the second processor 302 is configured to generate preset pulse parameters in different modes. The second processor 302 controls the second charging coil to charge the second main battery and the second backup battery; the second processor 302 controls the second backup battery to also charge the second main battery. The second temperature sensor measures a second charging temperature of the upper airway muscle stimulator 102. When the second charging temperature exceeds a threshold, charging of the second main battery is stopped by the second processor 302.
The wake-up module 303 is activated by the wake-up signal received by the second communication module 305 to wake up the upper airway muscle stimulator 102, preferably the wake-up module 303 also communicates a different mode wake-up signal to the second processor 302.
The second electrode 304 is provided at the upper airway muscle, and the second electrode 304 is electrically connected to the second pulse generator 202 to apply the electric stimulation pulse emitted from the second pulse generator 301 to the upper airway muscle, thereby dilating the upper airway.
The second communication module 305 is for wireless communication between the upper airway muscle stimulator 102 and the nerve electrical stimulator 101 and other devices, wherein the wireless communication may use any technology known in the art, such as RF or bluetooth, etc.
The first and second primary batteries and the first and second secondary batteries are lithium ion rechargeable batteries or other fast rechargeable batteries.
The overall workflow of the epileptic sleep apnea prevention system is described as follows:
(1) The first processor 204 controls the first pulse generator 202 to send electrical stimulation pulses to the first electrode 201 at preset pulse parameters under the selected treatment regimen to electrically stimulate the neural target of the patient P;
(2) Meanwhile, the respiratory parameter acquisition device 203 acquires physiological parameters of the patient P, and the first processor 204 judges the respiratory state of the patient P according to the physiological parameters;
(3) When the first processor 204 determines that sleep apnea is occurring, a wake signal is generated, preferably, the first processor 204 further determines the severity of sleep apnea and generates a different mode wake signal;
(4) The wake-up module 303 is activated by the first communication module 204 communicating with the second communication module 305;
(5) The wake-up module 303 wakes up the upper airway muscle stimulator 102, preferably the wake-up module 303 also transmits a wake-up signal of a different mode to the second processor 302;
(6) The second processor 302 controls the second pulse generator 302 to send electrical stimulation pulses to the second electrode 304 to electrically stimulate the upper airway muscles of the patient P with preset pulse parameters, preferably with preset pulse parameters in different modes.
Second embodiment:
the epileptic sleep apnea preventing system further includes an external pre-warning controller 103 in addition to the nerve electric stimulator 101 and the upper airway muscle stimulator 102, which are the same as those of the previous embodiment, and the external pre-warning controller 103 is used for pre-warning the patient. The external pre-warning controller 103 can wirelessly communicate with the first communication module 205 of the nerve electric stimulator 101 and the second communication module 305 of the upper airway muscle stimulator 102 through the communication module built therein.
The workflow of the epileptic sleep apnea preventing system incorporating the external pre-warning controller 103 includes the following steps in addition to the steps (1) - (6) above:
(7) When the upper airway muscle stimulator 102 is awakened for upper airway muscle stimulation for a period of time Tla, the first processor 204 determines whether there is a relief from the sleep apnea condition, preferably using an increase in blood oxygen saturation above a threshold BOla as a measure of the relief from the sleep apnea condition, preferably Tla is 120-240 seconds and BOla is 3% -8%. ,
(8) If the first processor 204 judges that the sleep apnea is still continuous, communicating with the external early warning controller 103;
(9) The external early warning controller 103 wakes up the patient, preferably, the specific mode adopted for waking up the patient is that the external early warning controller 103 is used for communicating with the nerve electric stimulator 101, and the first processor 204 is used for setting a wake-up pulse parameter for the first pulse generator 202, and the wake-up pulse parameter can generate electric pulse stimulation which can wake up the patient but does not damage the patient, so as to wake up the patient by electric stimulation, or the specific mode adopted for waking up the patient is that an alarm module of the external early warning controller 103 is used for sending out a sound alarm with a certain amplitude, so as to wake up the patient by sound alarm, or the specific mode adopted for waking up the patient is that the electric stimulation is firstly adopted for waking up, and then the sound alarm is adopted for waking up after invalidation.
Further, the external pre-warning controller 103 can also be used as a common patient controller, so that the patient P can manually adjust the pulse parameters of the nerve electric stimulator 101 and the upper airway muscle stimulator 102, respectively, when necessary.
Claims (6)
1. A rechargeable implantable stimulation system comprising a vagus nerve stimulator and an upper airway muscle stimulator, characterized by: the vagus nerve stimulator (101) comprises a first electrode (201), a first pulse generator (202), a breathing parameter acquisition device (203), a first charging coil, a first main battery, a first standby battery, a first temperature sensor, a first processor (204) and a first communication module (205), wherein the first electrode (201) is wound on a vagus nerve; -the first processor (204) controls the first charging coil to charge the first main battery and the first backup battery; the first processor (204) controls the first backup battery to charge the first main battery; the first temperature sensor measures a first charging temperature of the vagus nerve stimulator (101); the upper airway muscle stimulator (102) comprises a second pulse generator (301), a second processor (302), a wake-up module (303), a second temperature sensor, a second charging coil, a second main battery, a second standby battery, a second electrode (304) and a second communication module (305); the second electrode (304) is located at an upper airway muscle; -the second processor (302) controls the second charging coil to charge the second main battery and the second backup battery; -the second processor (302) controls the second backup battery to charge the second main battery, the second temperature sensor measuring a second charging temperature of the upper airway muscle stimulator (102);
the first processor (204) controls the first pulse generator (202) to send pulses to the first electrode (201) wound around the vagus nerve for stimulation according to preset parameters when a patient sleeps, meanwhile, the respiratory parameter collection device (203) collects respiratory parameter blood oxygen saturation, judges whether the blood oxygen saturation is lower than a choking threshold, and when the blood oxygen saturation is lower than the choking threshold, the first communication module (205) communicates with the second communication module (305), the wake-up module (303) is activated, the upper airway muscle stimulator (102) is woken up, and the second processor (302) controls the second pulse generator (301) to send pulses to the second electrode (304) at the upper airway muscle according to preset parameters; the vagus nerve stimulator (101) stimulates the vagus nerve to relieve epileptic symptoms, and when suffocation is about to occur, the upper airway muscle stimulator (102) is aroused to stimulate upper airway muscles, expand the upper airway and prevent the occurrence of the suffocation;
when the upper airway muscle stimulator (102) stimulates that the blood oxygen saturation has not risen to a certain threshold for a period of time, communicating with the vagal nerve stimulator (101), the first processor (204) sets a pulse generator parameter to an amplitude that can wake up the patient but is not damaging to the patient, thereby waking up the patient.
2. The rechargeable implant stimulation system according to claim 1, wherein: stopping charging the first main battery by the first processor (204) when the first charging temperature exceeds a threshold; when the second charging temperature exceeds a threshold, charging of the second main battery is stopped by the second processor (302).
3. The rechargeable implant stimulation system according to claim 1, wherein: the implantation stimulation system is provided with an external early warning controller (103), and when the upper airway muscle stimulator (102) stimulates that the blood oxygen saturation does not rise to a certain threshold value for a period of time, early warning is carried out through the external early warning controller (103).
4. The rechargeable implant stimulation system according to claim 2, wherein: the implant stimulation system is configured with an external pre-warning controller (103), the external pre-warning controller (103) being operable to control pulse parameters of the first pulse generator (202) and the second pulse generator (301).
5. The rechargeable implant stimulation system according to claim 1, wherein: the vagus nerve stimulator (101) can be replaced by a deep brain electric stimulator, and can also relieve epileptic symptoms.
6. The rechargeable implant stimulation system according to claim 1, wherein: the first and second primary batteries and the first and second backup batteries are lithium ion rechargeable batteries.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611194592.0A CN106669033B (en) | 2016-12-22 | 2016-12-22 | Epileptic sleep apnea preventing system capable of being charged safely and rapidly |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611194592.0A CN106669033B (en) | 2016-12-22 | 2016-12-22 | Epileptic sleep apnea preventing system capable of being charged safely and rapidly |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106669033A CN106669033A (en) | 2017-05-17 |
| CN106669033B true CN106669033B (en) | 2023-05-02 |
Family
ID=58870096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611194592.0A Active CN106669033B (en) | 2016-12-22 | 2016-12-22 | Epileptic sleep apnea preventing system capable of being charged safely and rapidly |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106669033B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158080A (en) * | 1990-11-08 | 1992-10-27 | Medtronic, Inc. | Muscle tone |
| CN101939043A (en) * | 2007-10-09 | 2011-01-05 | 伊姆特拉医疗公司 | Devices, systems and methods for selective stimulation |
| CN104080510A (en) * | 2011-09-30 | 2014-10-01 | 尼科索亚股份有限公司 | Apparatus and method for detecting a sleep disordered breathing precursor |
| CN104508343A (en) * | 2012-01-26 | 2015-04-08 | Med-El电气医疗器械有限公司 | Neural monitoring methods and systems for treating pharyngeal disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7680538B2 (en) * | 2005-03-31 | 2010-03-16 | Case Western Reserve University | Method of treating obstructive sleep apnea using electrical nerve stimulation |
| US7672728B2 (en) * | 2005-12-28 | 2010-03-02 | Cardiac Pacemakers, Inc. | Neural stimulator to treat sleep disordered breathing |
| US20080021506A1 (en) * | 2006-05-09 | 2008-01-24 | Massachusetts General Hospital | Method and device for the electrical treatment of sleep apnea and snoring |
| CA2738479C (en) * | 2008-10-09 | 2017-11-28 | Imthera Medical, Inc. | Method of stimulating a hypoglossal nerve for controlling the position of a patient's tongue |
| CA2753356A1 (en) * | 2009-02-02 | 2010-08-05 | Neurostream Technologies General Partnership | A method and device for the prevention of sudden unexpected death in epilepsy (sudep) |
| AU2012347770A1 (en) * | 2011-12-07 | 2014-06-26 | Otologics, Llc | Sleep apnea control device |
| US9498627B2 (en) * | 2014-01-15 | 2016-11-22 | Pacesetter, Inc. | Wireless closed-loop and system to detect and treat sleep apnea |
| US9656083B2 (en) * | 2014-07-22 | 2017-05-23 | Imthera Medical, Inc. | Method for adjusting a system for stimulating a hypoglossal nerve |
| US20160354602A1 (en) * | 2015-06-05 | 2016-12-08 | The Alfred E. Mann Foundation For Scientific Research | Upper airway stimulator systems for obstructive sleep apnea |
-
2016
- 2016-12-22 CN CN201611194592.0A patent/CN106669033B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158080A (en) * | 1990-11-08 | 1992-10-27 | Medtronic, Inc. | Muscle tone |
| CN101939043A (en) * | 2007-10-09 | 2011-01-05 | 伊姆特拉医疗公司 | Devices, systems and methods for selective stimulation |
| CN104080510A (en) * | 2011-09-30 | 2014-10-01 | 尼科索亚股份有限公司 | Apparatus and method for detecting a sleep disordered breathing precursor |
| CN104508343A (en) * | 2012-01-26 | 2015-04-08 | Med-El电气医疗器械有限公司 | Neural monitoring methods and systems for treating pharyngeal disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106669033A (en) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12102833B2 (en) | Medical device recharging based on patient activity | |
| US12527956B2 (en) | Methods and systems for monitoring or assessing movement disorders or other physiological parameters using a stimulation system | |
| US9168374B2 (en) | Intra-burst pulse variation for stimulation therapy | |
| US7643881B2 (en) | Neurostimulation with activation based on changes in body temperature | |
| JP3571651B2 (en) | Activation of the cardiac activity algorithm of the neural stimulator | |
| EP2701583B1 (en) | Dynamic heart rate threshold for neurological event detection | |
| CN106730336B (en) | Epileptic sleep apnea prevention system | |
| KR20120101650A (en) | System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue | |
| CN103785105B (en) | A kind of patient controller, implantable nerve stimulating system and feedback regulation method | |
| CN106787133A (en) | A kind of implanted device battery management system | |
| CN106532854A (en) | Battery management system for implantable apparatus | |
| CN106787134A (en) | A kind of implanted device battery management system | |
| CN106669032B (en) | A fast-chargeable sleep apnea prevention system for snoring | |
| CN106730342B (en) | Implanted sacral nerve stimulator with electrode displacement prompt function | |
| CN106823140B (en) | Sacral nerve stimulator capable of adjusting electric field direction | |
| CN106669033B (en) | Epileptic sleep apnea preventing system capable of being charged safely and rapidly | |
| CN106492347B (en) | A fast-chargeable vagus nerve stimulator electronic prescription dispensing system | |
| CN106726091B (en) | Epileptic sleep apnea prevention system capable of achieving quick charging | |
| CN106730337A (en) | A kind of vagus nerve stimulator electronic prescription configuration system of quickly-chargeable | |
| CN106684983A (en) | An implanted device battery management system | |
| CN106726090B (en) | Rechargeable snoring sleep apnea prevention system | |
| US20240342479A1 (en) | Automatic titration with defibrillation sensitivity compensation | |
| CN102451520B (en) | Implantable electronic device with vibration alarm function, and medical system | |
| CN120084491A (en) | A sealing detection method, device and storage medium for an implantable pulse generator | |
| CN116850458A (en) | Implanted electronic device with voice/vibration reminding function and medical system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 102200 building 19, Zhongke Yungu Park, No. 79, Shuangying West Road, Science Park, Changping District, Beijing Patentee after: Beijing Pinchi Medical Equipment Co.,Ltd. Country or region after: China Address before: 102200 building 19, Zhongke Yungu Park, No. 79, Shuangying West Road, Science Park, Changping District, Beijing Patentee before: BEIJING PINS MEDICAL Co.,Ltd. Country or region before: China |
|
| CP03 | Change of name, title or address |